Patients Benefit From Genetics-Guided Coumarin Anticoagulant Therapy

A. H. Maitland-van der Zee; A. K. Daly; F. Kamali; V. G. Manolopoulous; V. G. Manolopoulos; T. I. Verhoef; M. Wadelius; A. [=Anthonius] de Boer; M. Pirmohamed

doi:https://doi.org/10.1038/clpt.2014.44

Patients Benefit From Genetics-Guided Coumarin Anticoagulant Therapy

A. H. Maitland-van der Zee, A. K. Daly, F. Kamali, V. G. Manolopoulous, V. G. Manolopoulos, T. I. Verhoef, M. Wadelius, A. [=Anthonius] de Boer, M. Pirmohamed

Research output: Contribution to journal › Editorial › Academic › peer-review

17 Citations (Scopus)

Abstract

Observational studies have overwhelmingly shown that variants in the genes CYP2C9 and VKORC1 are significant determinants of individual dose of coumarin anticoagulants needed to maintain a therapeutic international normalized ratio (INR).(1) Until recently, however, few randomized clinical trials had been performed relating to the use of genetic data to predict dosing. Three sucsh clinical trials have now reported their findings

Original language	English
Pages (from-to)	15-17
Journal	Clinical Pharmacology and Therapeutics
Volume	96
Issue number	1
DOIs	https://doi.org/10.1038/clpt.2014.44
Publication status	Published - 2014
Externally published	Yes

Access to Document

https://doi.org/10.1038/clpt.2014.44

Cite this

@article{cb0630098405440faa95e360093531cb,

title = "Patients Benefit From Genetics-Guided Coumarin Anticoagulant Therapy",

abstract = "Observational studies have overwhelmingly shown that variants in the genes CYP2C9 and VKORC1 are significant determinants of individual dose of coumarin anticoagulants needed to maintain a therapeutic international normalized ratio (INR).(1) Until recently, however, few randomized clinical trials had been performed relating to the use of genetic data to predict dosing. Three sucsh clinical trials have now reported their findings",

author = "{Maitland-van der Zee}, {A. H.} and Daly, {A. K.} and F. Kamali and Manolopoulous, {V. G.} and Manolopoulos, {V. G.} and Verhoef, {T. I.} and M. Wadelius and {de Boer}, {A. [=Anthonius]} and M. Pirmohamed",

year = "2014",

doi = "https://doi.org/10.1038/clpt.2014.44",

language = "English",

volume = "96",

pages = "15--17",

journal = "Clinical Pharmacology and Therapeutics",

issn = "0009-9236",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Patients Benefit From Genetics-Guided Coumarin Anticoagulant Therapy

AU - Maitland-van der Zee, A. H.

AU - Daly, A. K.

AU - Kamali, F.

AU - Manolopoulous, V. G.

AU - Manolopoulos, V. G.

AU - Verhoef, T. I.

AU - Wadelius, M.

AU - de Boer, A. [=Anthonius]

AU - Pirmohamed, M.

PY - 2014

Y1 - 2014

N2 - Observational studies have overwhelmingly shown that variants in the genes CYP2C9 and VKORC1 are significant determinants of individual dose of coumarin anticoagulants needed to maintain a therapeutic international normalized ratio (INR).(1) Until recently, however, few randomized clinical trials had been performed relating to the use of genetic data to predict dosing. Three sucsh clinical trials have now reported their findings

AB - Observational studies have overwhelmingly shown that variants in the genes CYP2C9 and VKORC1 are significant determinants of individual dose of coumarin anticoagulants needed to maintain a therapeutic international normalized ratio (INR).(1) Until recently, however, few randomized clinical trials had been performed relating to the use of genetic data to predict dosing. Three sucsh clinical trials have now reported their findings

U2 - https://doi.org/10.1038/clpt.2014.44

DO - https://doi.org/10.1038/clpt.2014.44

M3 - Editorial

C2 - 24942396

SN - 0009-9236

VL - 96

SP - 15

EP - 17

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

IS - 1

ER -